Coronavirus Disease-19 in a patient with minimal change nephrotic syndrome undergoing rituximab monotherapy.

Suzuki, Tomo; Nagaoka, Kanako; Takahashi, Yoshinori; Osawa, Ryosuke; Hosokawa, Naoto

Suzuki, Tomo; Nagaoka, Kanako; Takahashi, Yoshinori; Osawa, Ryosuke; Hosokawa, Naoto.

Suzuki T; Department of Nephrology, Kameda Medical Center, Kamogawa, Japan.
Nagaoka K; Department of Nephrology, Kameda Medical Center, Kamogawa, Japan.
Takahashi Y; Department of Infectious Diseases, Kameda Medical Center, Kamogawa, Japan.
Osawa R; Department of Infectious Diseases, Kameda Medical Center, Kamogawa, Japan.
Hosokawa N; Department of Infectious Diseases, Kameda Medical Center, Kamogawa, Japan.

Saudi J Kidney Dis Transpl ; 32(5): 1505-1506, 2021.

Article in English | MEDLINE | ID: covidwho-1835078

Subject(s)

COVID-19; Nephrosis, Lipoid; Nephrotic Syndrome; Female; Humans; Immunologic Factors; Male; Nephrosis, Lipoid/complications; Nephrosis, Lipoid/diagnosis; Nephrosis, Lipoid/drug therapy; Nephrotic Syndrome/diagnosis; Nephrotic Syndrome/drug therapy; Recurrence; Rituximab/therapeutic use; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Nephrosis, Lipoid / Nephrotic Syndrome Type of study: Diagnostic study / Prognostic study Topics: Long Covid Limits: Female / Humans / Male Language: English Journal: Saudi J Kidney Dis Transpl Year: 2021 Document Type: Article Affiliation country: 1319-2442.344780

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google